Earnings call transcript: Eureka Forbes posts strong Q2 2027 growth, shares slip

Eureka Forbes reported Q2 FY2027 revenue of INR 890 crore, up 15% year on year, and record quarterly PAT of INR 73 crore, up 19.1%; adjusted EBITDA margin expanded 43 bps to 13.6%. Gross margin fell 138 bps to 55.1% amid commodity inflation, and management expects a transitionary Q3 margin impact before a planned 3%–4% price increase takes fuller effect in Q4; it maintained its full-year flat-margin target and expects H2 growth to accelerate. Shares fell 1.11% to $343.95 after the update.

Analysis

The key earnings-quality question is whether Eureka Forbes can turn lower-cost, longer-life purifier products into incremental category entry without hollowing out its service annuity. Two- and four-year filter cycles may reduce near-term service frequency; management’s higher lifetime-value case depends on first-time buyers staying on-network and converting to genuine replacements or AMCs—cohort evidence is not yet available. That proof point is likely months to years away, not this quarter.

Near term, the margin risk is asymmetric: input-cost inflation is already flowing through gross margin, while the announced pricing is delayed and may test volume elasticity, especially in economy products. Q3 is therefore an execution test; a Q4 recovery requires both price realization and continued sell-through, not just channel loading. Competitive launches could limit pass-through. Conversely, easing input costs would let operating leverage show through faster than the cautious outlook implies.

The stock’s muted response is not confirmation that fundamentals are fully discounted; the supplied forecast figures are not comparable to the reported INR results, so no reliable beat/miss inference is possible. A separate potential overhang is the promoter pledge issue raised on the call: management disclaimed company-level liability, but unresolved pledge terms can still widen the minority-shareholder governance discount. Verify the filing and collateral terms before treating this as immaterial.

Key Decisions for Investors

• Avoid chasing the quarter; keep Eureka Forbes on a catalyst watch through Q3 and reassess after results for realized pricing, product sell-through, and gross-margin direction. No defensible entry level or valuation conclusion is available from the supplied data.
• Treat a long position as conditional on Q4 gross-margin recovery alongside sustained volume growth. Thesis weakens if price increases fail to offset input costs, water-purifier volumes decelerate materially, or full-year margin performance falls short of management’s flat-margin aim.
• Track service revenue and filter/AMC renewal cohorts over the next 6–18 months. The structural upside case is stronger if newer long-life products add first-time customers and later convert to on-network revenue; rising hardware sales without service recovery would challenge the lifetime-value thesis.
• Request the promoter-pledge amount, lender, collateral terms, and release timetable from exchange disclosures. Persistent or rising encumbrance could pressure the stock independently of operating results; do not assume it creates a direct company liability.